Drugs /

tretinoin

Back to Drugs List

Overview

Generic Name(s):
tretinoin
Trade Name(s):
Atra, Avita, Stieva-A, Dermairol, Cordes Vas, Aberel, Retin-A, Retisol-A, Aknoten, Retin-A Micro, Vesanoid, Airol, Renova, Eudyna, Stieva-A Forte, Vitinoin, and Epi-Aberel
NCI Definition [1]:
A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties.

Clinical Trials

View Clinical Trials for tretinoin

Tretinoin has been investigated in 12 clinical trials, of which 8 are open and 4 are closed. Of the trials investigating tretinoin, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (3 open), and 2 are phase 3 (2 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for tretinoin clinical trials.

Acute myeloid leukemia, acute promyelocytic leukemia, and acute lymphoblastic leukemia are the most common diseases being investigated in tretinoin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tretinoin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tretinoin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tretinoin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Airol, 34987, Retin-A MICRO, all-trans-beta-retinoic acid, tretinoinum, all trans-retinoic acid, tretinoin (product), vitamin a acid, all-trans-, all trans retinoic acid, tretinoin, all-trans retinoic acid, all-trans-vitamin a acid, 302-79-4, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl), trans retinoic acid, retionic acid, trans-retinoic acid, all-trans-tretinoin, retinoic acid, vitamin a acid, all trans-retinoic acid, beta-retinoic acid, tretinoin (substance), vitamin a acid, all-trans retinoic acid, retin-a-micro, trans retinoic acid, acide retinoique (french) (dsl), retinoic acid, all-trans-retinoic acid, Aberel, Aknoten, ATRA, Avita, Renova, Retin-A, Vesanoid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Retisol-A, Stieva-A, Stieva-A Forte, Vitinoin, all-trans-vitamin a1 acid, trétinoïne, trans vitamin a acid, acid, vitamin a, all-trans vitamin a acid, (all-e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, all-trans-retinoic acid, all trans retinoic acid, tretin m, retinoic acid, 122758, acid, trans-retinoic, 2,4,6,8-nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-e)-, beta-retinoic acid, retin-a micro brand of tretinoin, all-(e)-retinoic acid, tretinoin [chemical/ingredient], stieva-a, retinoic acid, tretinoinum, trans vitamin a acid, all-trans vitamin a acid, (all-e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, trans retinoic acid, (all-e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, vitamin a acid, tretinoina, all-trans-vitamin a acid, beta-retinoic acid, ro 5488, acid, retinoic, retin-a, tretinoine (french) (einecs), tretinoin, retin a, acid, all-trans-retinoic, trans-retinoic acid, tra
Drug Categories [2]:
Differentiation inducers
NCIT ID [1]:
C900
SNOMED ID [1]:
C-92010

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.